Age-related macular degeneration: current treatment and future options

1. Tanya Moutray⇓

1. Directorate of Ophthalmology, Head and Skeletal Division, Royal Victoria Hospital Belfast, Belfast BT12 6BA, UK

1. tanya.moutray@googlemail.com

1. Usha Chakravarthy

1. Directorate of Ophthalmology, Head and Skeletal Division, Royal Victoria Hospital Belfast, and Centre for Vision and Vascular Science, The Queen's University of Belfast, Belfast, UK

Abstract

Age-related macular degeneration is the leading cause of visual impairment among older adults in the developed world. Epidemiological studies have revealed a number of genetic, ocular and environmental risk factors for this condition, which can be addressed by disease reduction strategies. We discuss the various treatment options for dry and exudative age-related macular degeneration available and explain how the recommended treatment depends on the exact type, location and extent of the degeneration. Currently, vascular endothelial growth factor (VEGF) inhibition therapy is the best available treatment for exudative age-related macular degeneration but is limited by the need for repeated intravitreal injections. The current treatment regime is being refined through research on optimal treatment frequency and duration and type of anti-VEGF drug. Different modes of drug delivery are being developed and in the future other methods of VEGF inhibition may be used.

Age-related macular degeneration: current treatment and future options